Leukemia kills about a third of the people diagnosed with it, but that single number hides enormous variation. The overall five-year survival rate for all leukemia types combined is 68.6%, according to the National Cancer Institute’s SEER database. That means roughly 7 in 10 people are alive five years after diagnosis. Whether leukemia is a manageable condition or a rapidly fatal one depends almost entirely on which type you have, how old you are, and the specific genetic features of your cancer cells.
How Survival Differs by Type
There are four main types of leukemia, and they range from highly curable to stubbornly lethal. The distinction between “acute” and “chronic” matters more than almost any other factor. Acute leukemias progress fast and require immediate, aggressive treatment. Chronic leukemias develop slowly, sometimes over years, and some people live decades with them.
Chronic lymphocytic leukemia (CLL) has the best outlook, with a five-year survival rate around 89.5%. Many people with early-stage CLL don’t need treatment right away and have a median survival of over 12 years from diagnosis. Chronic myeloid leukemia (CML) was once one of the deadliest forms, with only a 17.2% five-year survival rate in 1975. The introduction of targeted therapy in the early 2000s transformed it into a largely manageable disease, pushing survival to 72.8%. Most CML patients today die of causes unrelated to their leukemia.
Acute lymphoblastic leukemia (ALL) has a five-year survival rate of about 69.5% overall, but this number is heavily shaped by age. In children and teens, it’s one of the most curable cancers, with more than 90% of patients alive at five years and roughly 85% never relapsing. In adults, especially older adults, the picture is considerably worse.
Acute myeloid leukemia (AML) remains the most lethal common type. Its five-year survival rate is still under 35%, and for people over 60, population-based studies report five-year survival of only 3 to 8%.
Why Age Changes Everything
Age is the single strongest predictor of whether leukemia will be fatal, particularly in AML. A person diagnosed with AML before age 56 has a median overall survival of about 19 months. For someone between 66 and 75, that drops to roughly 7 months. For those older than 75, the median is just 3.5 months.
This isn’t only because older bodies tolerate chemotherapy less well, though that plays a role. The biology of the disease itself gets worse with age. In younger AML patients, about 17% have genetic changes in their cancer cells that respond well to treatment. By age 75 and older, only 4% have those favorable genetic features. Meanwhile, the proportion of patients with high-risk genetic patterns climbs from 35% in younger patients to 51% in those over 75. Older patients’ leukemia cells are also more likely to resist chemotherapy through a mechanism called multidrug resistance, found in about a third of younger patients but nearly 60% of those over 56.
Physical fitness at diagnosis matters too. Among patients of any age who are in excellent physical condition, early treatment death is relatively uncommon. But for patients over 75 who are already in poor health at diagnosis, 82% die within the first 30 days of starting treatment.
CLL: A Wide Range of Outcomes
Chronic lymphocytic leukemia deserves its own discussion because it behaves so differently depending on how advanced it is when found. Early-stage CLL (stage 0) has a median survival of 150 months, over 12 years, and many of those patients are simply monitored without treatment. At the other end, advanced CLL (stages III and IV) carries a median survival of only about 19 months, with most patients dying within four years.
This means two people with “leukemia” can have wildly different realities. One might live a normal lifespan with periodic blood tests. The other might face an urgent, life-threatening illness. The staging at diagnosis, along with certain genetic markers in the cancer cells, determines which category a person falls into.
How Much Has Survival Improved
Leukemia is far less deadly than it was a generation ago. In 1975, the overall five-year survival rate was just 33.3%, meaning two out of three patients died within five years. By 2018, that figure had climbed to 73.1%. Death rates for people under 45 have declined steadily over the past two decades with minimal differences across demographic groups.
The most dramatic gains have come in specific subtypes. CML’s transformation from a near-certain death sentence to a chronic, manageable condition is one of the biggest success stories in cancer medicine. Childhood ALL went from majority-fatal to over 90% survival. Even CLL survival improved by about 32% between 1975 and 2012.
AML in older adults remains the major holdout. While survival has improved modestly across all age groups, the gains for people over 60 with AML have been small. This is the form of leukemia that still behaves the way most people fear when they hear the word.
What Determines Your Individual Risk
Beyond type and age, several factors shape how dangerous a leukemia diagnosis is for any individual person:
- Genetic features of the cancer cells. Specific chromosome changes in the leukemia cells are one of the strongest predictors of outcome. Some patterns respond well to treatment, while others are associated with resistance and relapse.
- White blood cell count at diagnosis. A very high count at the time of diagnosis is generally associated with more aggressive disease.
- Overall health and fitness. People who are physically strong at diagnosis tolerate treatment better and have significantly lower early death rates, regardless of age.
- How quickly the cancer responds to initial treatment. Achieving remission after the first round of therapy is one of the clearest signals of a good long-term outcome.
The gap between the best-case and worst-case scenarios in leukemia is wider than in almost any other cancer. A child with ALL or an adult with early CLL can reasonably expect to live a full life. An older adult with AML facing unfavorable genetics is dealing with one of the most aggressive cancers that exists. The word “leukemia” covers all of these realities, which is why a single survival number never tells the full story.